Anti-Human CD19 Recombinant Antibody(Inebilizumab)
-
产品编号
YR1374
-
别名
科研级 Inebilizumab ( 英比利珠单抗 ), Anti-CD19 Recombinant Antibody, Research Grade Inebilizumab
-
规格
- 1mg
- 5mg
产品介绍
| Alias | 科研级 Inebilizumab ( 英比利珠单抗 ), Anti-CD19 Recombinant Antibody, Research Grade Inebilizumab |
| Catalog Number | YR1374 |
| Molecular Name | Inebilizumab |
| Size | 1mg, 5mg |
| Clonity | Monoclonal |
| Purity | >95% as determined by SDS-PAGE |
| Concentration | 1mg/ml |
| Antibody Isotype | IgG1 Kappa |
| Formulation | PBS, pH7.5 |
| Background | Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults.The most common adverse reactions include urinary tract infection, headache, joint pain (arthralgia), nausea and back pain. |
| CAS Number | 1299440-37-1 |
| Storage Condition | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
| Remarks | This product is for research use only. |
| Shipping Condition | Shipped on ice packs. |
| Target | CD19[Homo sapiens] |
- 联系我们
- 电话：400-621-6806
- 手机：13116038708
- 邮箱：info@kmdbioscience.com
- 地址：天津市武清区国际企业社区A5号楼
-
销售微信
-
官方公众号
-
400-621-6806 -
614353794 -
周一至周五 9:00-18:00 -
-
0
-
